Exagen Inc. (XGN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Exagen Inc. is a medical technology company focused on the AVISE® brand of testing products for the differential diagnosis and monitoring of rheumatic and autoimmune diseases, primarily systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This report covers the quarterly period ended June 30, 2025. The company operates a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $17.2 million | $15.1 million | $32.7 million | $29.5 million |
| Gross Margin | $10.4 million (60.4%) | $9.1 million (60.1%) | $19.5 million (59.7%) | $17.7 million (59.9%) |
| Net Loss | $(4.4) million | $(3.0) million | $(8.2) million | $(6.3) million |
| Diluted EPS | $(0.21) | $(0.16) | $(0.41) | $(0.35) |
| Cash & Equivalents | $30.0 million (as of June 30, 2025) | |||
| Total Debt (Carrying Value) | $22.3 million (Non-current) + $0.7 million (Current) | |||
| Operating Cash Flow | N/A | $(13.6) million | $(11.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14.2% QoQ and 10.9% YTD, driven by a 7% increase in test volume and a 7% increase in Average Selling Price (ASP) due to the January 2025 launch of new T-Cell and RA Sub-Profile biomarkers.
- Financing Activity: In April 2025, the company entered a $75.0 million term loan facility with Perceptive Credit Holdings, drawing an initial $25.0 million tranche. $19.7 million was used to fully repay the 2017 Term Loan, resulting in a $0.3 million loss on extinguishment of debt.
- Equity Raise: In May 2025, the company completed a public offering of 3.85 million shares at $5.25 per share, generating net proceeds of approximately $18.6 million.
- Expense Increases: Operating expenses rose due to increased headcount and outside services. Interest expense increased significantly due to the new Perceptive Term Loan Facility and amortization of debt discounts.
- Warrant Liability: A new warrant liability of $4.0 million was recorded related to the Perceptive Credit Agreement, with a $0.4 million increase in fair value recognized in the quarter.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing capital resources ($30.0 million cash) are sufficient to fund operations for at least the next 12 months. An additional $50.0 million is available under the Perceptive facility subject to revenue milestones.
- Product Pipeline: The company plans to commercially launch PAD4 biomarkers for RA by year-end 2025. Development continues on Lupus Nephritis, SLE Disease Activity, and Kidney Damage biomarkers.
- Reimbursement Risks: Revenue depends heavily on third-party payor reimbursement. The company faces uncertainty regarding a Local Coverage Determination (LCD) for its AVISE® Lupus test due to a federal regulatory freeze on new rules. Commercial payor denials remain a challenge.
- Debt Covenants: The Perceptive Term Loan requires maintaining a minimum unrestricted cash balance of $3.0 million and achieving specified quarterly net revenue levels. The company was in compliance as of June 30, 2025.
- Legal Proceedings: A qui tam case was dismissed with prejudice in July 2025 following a settlement with the DOJ in 2023.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the Perceptive Term Loan revenue milestones and minimum cash balance requirements ($3.0 million).
- Reimbursement Status: Monitor the status of the AVISE® Lupus Local Coverage Determination (LCD) application and the impact of the federal regulatory freeze on Medicare reimbursement.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $4.0 million warrant liability, which is marked-to-market quarterly.
- Customer Concentration: Review the concentration risk where Customer A and Customer B represented 23% and 16% of Q2 revenue, respectively.
- Cash Burn Rate: Evaluate the sustainability of the current operating cash burn (~$13.6 million YTD) against the $30.0 million cash balance and potential need for future capital raises.